Alain C Borczuk (Alain Borczuk)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 17

Top Topics

Network Analysis

Top Venues

Nature communications

medRxiv : the preprint server for health sciences

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

This page only lists publications with an associated author ORCID identifier.

Publications

Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 15 (1) (2024)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 15 (1) (2024)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 15 (1) (2024)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 14 (1) (2023)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 14 (1) (2023)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 14 (1) (2023)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 14 (1) (2023)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 14 (1) (2023)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 14 (1) (2023)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 14 (1) (2023)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 14 (1) (2023)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 14 (1) (2023)
Nasser K Altorki, Zachary H Walsh, Johannes C Melms, Jeffery L Port, Benjamin E Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J Sanfilippo, Vivek Mittal, Alain C Borczuk, Sylvia C Formenti, Benjamin Izar, Timothy E McGraw
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature communications 14 (1) (2023)
Seungyeul Yoo, Abhilasha Sinha, Dawei Yang, Nasser K Altorki, Radhika Tandon, Wenhui Wang, Deebly Chavez, Eunjee Lee, Ayushi S Patel, Takashi Sato, Ranran Kong, Bisen Ding, Eric E Schadt, Hideo Watanabe, Pierre P Massion, Alain C Borczuk, Jun Zhu, Charles A Powell
Integrative network analysis of early-stage lung adenocarcinoma identifies aurora kinase inhibition as interceptor of invasion and progression. Nature communications 13 (1) (2022)
André Figueiredo Rendeiro, Hiranmayi Ravichandran, Junbum Kim, Alain C Borczuk, Olivier Elemento, Robert E Schwartz
Persistent alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19. medRxiv : the preprint server for health sciences (2022)
Alain C Borczuk
Updates in grading and invasion assessment in lung adenocarcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (2021)
Daniel Butler, Christopher Mozsary, Cem Meydan, Jonathan Foox, Joel Rosiene, Alon Shaiber, David Danko, Ebrahim Afshinnekoo, Matthew MacKay, Fritz J Sedlazeck, Nikolay A Ivanov, Maria Sierra, Diana Pohle, Michael Zietz, Undina Gisladottir, Vijendra Ramlall, Evan T Sholle, Edward J Schenck, Craig D Westover, Ciaran Hassan, Krista Ryon, Benjamin Young, Chandrima Bhattacharya, Dianna L Ng, Andrea C Granados, Yale A Santos, Venice Servellita, Scot Federman, Phyllis Ruggiero, Arkarachai Fungtammasan, Chen-Shan Chin, Nathaniel M Pearson, Bradley W Langhorst, Nathan A Tanner, Youngmi Kim, Jason W Reeves, Tyler D Hether, Sarah E Warren, Michael Bailey, Justyna Gawrys, Dmitry Meleshko, Dong Xu, Mara Couto-Rodriguez, Dorottya Nagy-Szakal, Joseph Barrows, Heather Wells, Niamh B O'Hara, Jeffrey A Rosenfeld, Ying Chen, Peter A D Steel, Amos J Shemesh, Jenny Xiang, Jean Thierry-Mieg, Danielle Thierry-Mieg, Angelika Iftner, Daniela Bezdan, Elizabeth Sanchez, Thomas R Campion, John Sipley, Lin Cong, Arryn Craney, Priya Velu, Ari M Melnick, Sagi D Shapira, Iman Hajirasouliha, Alain C Borczuk, Thomas Iftner, Mirella Salvatore, Massimo Loda, Lars F Westblade, Melissa Cushing, Shixiu Wu, Shawn E Levy, Charles Y Chiu, Robert E Schwartz, Nicholas P Tatonetti, Hanna Rennert, Marcin Imielinski, Christopher E Mason
Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. Nature communications 12 (1) (2021)